GRACE :: Lung Cancer

SCLC

Denise Brock

ASCO 2017 – Lung Cancer – What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?

Share
H. Jack West, MD
Medical Director
Thoracic Oncology Program Swedish Cancer Institute
President & CEO, GRACE
Matthew Gubens, MD
Thoracic Oncologist
Thoracic Surgery and Oncology Clinic
UCSF Helen Diller Family Comprehensive Cancer Center
Jyoti D. Patel, MD
Director Thoracic Oncology
University of Chicago Medicine

 

Drs. H. Jack West, Medical Director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle, Washington and President and CEO of GRACE, Matthew Gubens, Thoracic Oncologist at the Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Center in San Francisco, California, and Jyoti Patel, Director of Thoracic Oncology at University of Chicago Medicine gathered post meeting to discuss new information from ASCO 2017 regarding lung cancer.   In this roundtable video, the doctors discuss What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?



 

 Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

  
   
                   

 


Denise Brock

Lung Cancer Video Library – SCLC – Novel Therapies In Small Cell Lung Cancer (SCLC): Lurbinectedin

Share

 

GRACE Cancer Video Library - Lung

 

H. Jack West, MD
President & CEO, GRACE

 

We are pleased to have GRACE’s Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute in Seattle, Washington, and President and CEO of GRACE bring 2017 updates to our Lung Cancer Video Library.  

In this latest video, Dr. West discusses exciting new advances in SCLC –  Novel Therapies In Small Cell Lung Cancer (SCLC): Lurbinectedin.  

 


 

 

 

 

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.


 We would like to thank the following companies for their support of this program

 

                

 

 

                        

 

 
 

 

 


  


Denise Brock

Lung Cancer Video Library – Spanish Language: Video #40 The General Approach to Extensive Stage Small Cell Cancer

Share
 
GRACE Cancer Video Library - Lung

 

We are pleased to continue this series of informational videos for our Spanish speaking community.  GRACE is pleased to welcome Dr. Rafael Santana-Davila, Assistant Professor with the University of Washington School of Medicine and Seattle Cancer Care Alliance.  In this 40th video for the Spanish lung cancer video library, Dr. Santana-Davila joined GRACE to discuss the general approach to extensive stage small cell lung cancer.  


 

 

 

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.


 

TRANSCRIPTS – Spanish and English
download transcripts
 

Los Principios de Tratamiento Cuando el Cáncer de Células Pequeñas está en Estadio Extendido

The General Approach to Extensive Stage Small Cell Cancer

 

Rafael Santana-Davila, MD
Assistant Professor of Medicine
University of Washington Seattle Cancer Care Alliance
Seattle, Washington

 

Spanish TRANSCRIPT

Cuando el cáncer de células pequeñas está en estadio extendido es básicamente cuando el cáncer está en otras partes del pulmón o en otras partes del cuerpo. En este tipo de cáncer, el principio no es curar al paciente si no tratar de extender su vida y mejorar la calidad de ésta. En la mayoría de los casos el principio es quimioterapia, hay varios tipos de ésta que se pueden usar pero dependen de la conversación del doctor con el paciente para que conozca los riesgos, beneficios y los efectos adversos de cada tipo de quimioterapia. Se dan regularmente dos ciclos de quimioterapia y después se vuelven a hacer estudios de imágenes para ver cómo está respondiendo el cáncer. Lo más común es dar cuatro ciclos de quimioterapia y después de esto se puede usar radiación para consolidar las ganancias que obtuvo la quimioterapia.


  

English TRANSCRIPT

When small cells lung cancer is in extensive stage is when the cancer cells are in other parts of the lung or even in other parts of the body. In this type of cancer, the goal is not to cure the patient but to try to extend their life and improve their life quality. In most cases the treatment suggested is chemotherapy, which has different types of approaches and they all depend on the conversation the doctor and the patient have in order for the patient to understand the risks, benefits and possible side effects. Regularly, we give two cycles of chemotherapy and then we make again imaging studies to see how the cancer is responding. Four cycles of chemotherapy are the most common treatment to give and then we use radiation to concentrate the good effects chemotherapy had in the cancer cells.


Denise Brock

Lung Cancer Video Library – Spanish Language: Video #39 General Approach to Limited Stage SCLC

Share
 
GRACE Cancer Video Library - Lung

 

We are pleased to continue this series of informational videos for our Spanish speaking community.  GRACE is pleased to welcome Dr. Rafael Santana-Davila, Assistant Professor with the University of Washington School of Medicine and Seattle Cancer Care Alliance.  In this 39th video for the Spanish lung cancer video library, Dr. Santana-Davila joined GRACE to discuss the general approach to limited stage small cell lung cancer.  


 

 

 

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.


 

TRANSCRIPTS – Spanish and English
download transcripts
 

Enfoque General Para El Estadio Limitado de Células Pequeñas de Cancer de Pulmón

General Approach to Limited Stage Small Cells Lung Cancer

 

Rafael Santana-Davila, MD
Assistant Professor of Medicine
University of Washington Seattle Cancer Care Alliance
Seattle, Washington

 

Spanish TRANSCRIPT

Cuando el cancer de células pequeñas se encuentra en estado limitado, el tratamiento es a base de radiación y quimioterapia al mismo tiempo (quimioterapia y radiación concurrente). Regularmente es cuatro a seis semanas de radiación con dos ciclos de quimioterapia al mismo tiempo. Una vez que ha pasado esto lo que esperamos es que se haya erradicado todo el cancer dentro del pulmón y curar a las personas. En algunos casos, también se da radiación al cerebro para prevenir que el cancer lo afecte, a esto se le llama por sus siglas en inglés: PCI.


  

English TRANSCRIPT

When the lung cancer of small cells is in limited stage we use at the same time a radiation and chemotherapy treatment (chemotherapy and radiation concurrent). Regularly, is four to six weeks of radiation with two cycles of chemotherapy at the same time. Once this is over, we hope the cancer is eradicated in the lung and the person is cured. In some cases, we also give PCI which is radiation to the brain to prevent its damage.


GRACE Video

Histology-Specific Recommendations – Large-Cell Neuroendocrine

Share
GRACE Cancer Video Library - Lung

GCVL_LU-F07_Histology_Specific_Recommendations_Large-Cell_Neuroendocrine

 

Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

Download Transcript

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

One of the less common subtypes of non-small cell lung cancer is known as large cell neuroendocrine, and it is in the same family as small cell lung cancer — these are all known as neuroendocrine cancers. They originate from cells that are in the middle of the body, in the middle of the chest, that have evolved to have hormone-secreting abilities. Because of that, large cell neuroendocrine and small cell lung cancer really share enough features that they are treated in a very similar way.

The standard approach for most patients with advanced non-small cell lung cancer for metastatic lung cancer, if you do not have a driver mutation like EGFR or ALK, is a two drug combination, a so-called platinum-based doublet with cisplatin or carboplatin in combination with a partner drug. For many subtypes of lung cancer, what that partner is doesn’t matter too much — the various combinations all produce very similar results. However we tend to make a very specific recommendation for patients with a large cell neuroendocrine cancer and in fact we treat it very much like we would a small cell lung cancer.

For decades we’ve known that cisplatin or carboplatin in combination with a drug known as etoposide is a very effective treatment approach for small cell lung cancer and because large cell neuroendocrine is in the same family and has so many similar features, the most common recommended approach in terms of the chemotherapy that we would favor is cisplatin or carboplatin in combination with etoposide. Other options are certainly reasonable, but they are not as commonly recommended.

Unfortunately we don’t have a lot of actual research yet on the best approaches for patients with advanced large cell neuroendocrine cancers, but we’re starting to look into that for the first time in a very meaningful way. Until we have those results, we really do tend to favor a platinum and etoposide approach.


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243